The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 11, 2021

Filed:

Mar. 25, 2020
Applicant:

Marinus Pharmaceuticals Inc., Radnor, PA (US);

Inventors:

Christopher Cashman, Radnor, PA (US);

Jaakko Lappalainen, Radnor, PA (US);

David A. Czekai, Radnor, PA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/57 (2006.01); A61K 31/565 (2006.01); A61K 31/573 (2006.01); C07J 7/00 (2006.01); A61K 45/06 (2006.01); A61K 31/5513 (2006.01); A61K 47/36 (2006.01); A61K 47/69 (2017.01); A61K 47/32 (2006.01); A61K 47/10 (2017.01); A61K 9/00 (2006.01); C08B 37/16 (2006.01); A61K 47/38 (2006.01); A61K 9/107 (2006.01); A61K 31/718 (2006.01); A61K 31/721 (2006.01);
U.S. Cl.
CPC ...
A61K 31/573 (2013.01); A61K 9/0019 (2013.01); A61K 9/1075 (2013.01); A61K 31/5513 (2013.01); A61K 31/57 (2013.01); A61K 45/06 (2013.01); A61K 47/10 (2013.01); A61K 47/32 (2013.01); A61K 47/36 (2013.01); A61K 47/38 (2013.01); A61K 47/6951 (2017.08); C07J 7/009 (2013.01); C08B 37/0015 (2013.01); A61K 31/718 (2013.01); A61K 31/721 (2013.01);
Abstract

The disclosure provides a method of treating a patient having postpartum depression, premenstrual dysphoric disorder, menopausal depression, or delirium tremens comprising administering an effective amount of an injectable neurosteroid formulation to the patient. In certain embodiments the injectable neurosteroid formulation is an injectable ganaxolone formulation. Two types of injectable neurosteroid formulations may be used in the disclosed methods. The first such formulation is an injectable formulation containing ganaxolone and sulfobutyl ether β-cyclodextrin in a 1:1 inclusion complex. The second such formulation is an injectable neurosteroid formulation comprising a neurosteroid, preferably ganaxolone, but which may be a neurosteroid selected from allopregnanolone, ganaxolone, alphaxalone, alphadolone, hydroxydione, minaxolone, pregnanolone, tetrahydrocorticosterone, and combinations of the foregoing; a surface stabilizer selected from hydroxyl ethyl starch, dextran, and povidone; and a surfactant.


Find Patent Forward Citations

Loading…